IRVINE, Calif., Aug 24, 2010 -- Smokefree Innotec, Inc. (PINKSHEETS: SFIO) Thomas Schroepfer, CEO, (http://www.sfio.us or http://www.realsmokefree.com) announced today the retention of a well-known European public relations company, Perfect Entertainment Group.
Smokefree Innotec, Inc. closed at $0.005 Wednesday, trading 2,392,116 shares.
Smokefree Innotec Retains Perfect Entertainment Group for European PR
About Smokefree Innotec, Inc
Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing hi-tech, nicotine and non-nicotine cigarette-like delivery devices which are completely smoke and vapor-free and tobacco-free. Smokefree Innotec's products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking tobacco or similar substances is prohibited. Further, our products will allow the smoker to enjoy smoking either nicotine or flavored non-nicotine cigarettes while not having to worry about the offensive dangers and ill effects of regular cigarette smoking. However Smokefree Innotec products are not intended for any prevention or therapeutic treatment of any disease.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
OCEANSIDE, Calif., Aug 26, 2010 -- International Stem Cell Corporation (OTCBB: ISCO), announced today that the recent action of a federal district judge blocking federal funding of embryonic stem cell research is not expected to have negative effects on ISCO's therapeutic programs using its human parthenogenetic stem cells.
International Stem Cell Corporation closed at $1.03 Wednesday, trading 181,354 shares.
International Stem Cell Corporation Not Adversely Affected by Stem Cell Research Funding Ban
About International Stem Cell Corporation
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike all other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals across racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, develops a line of cosmeceutical products via its subsidiary Lifeline Skin Care and advances novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics do not. More information is available at ISCO's website, internationalstemcell.com.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer
-------------------------------------------
Posts
No comments:
Post a Comment